LT3150580T - Aril- arba heteroaril-pakeistieji benzeno junginiai - Google Patents

Aril- arba heteroaril-pakeistieji benzeno junginiai

Info

Publication number: LT3150580T
Authority: LT; Lithuania
Prior art keywords: heteroaryl; aryl; substituted benzene; benzene compounds; compounds
Prior art date: 2011-04-13

Application number

LTEP16172386.1T

Other languages

English (en)

Inventor

Kevin Wayne Kuntz

Richard Chesworth

Kenneth William Duncan

Heike KEILHACK

Natalie WARHOLIC

Christine KLAUS

Masashi Seki

Syuji SHIROTORI

Satoshi Kawano

Timothy James Nelson Wigle

Sarah Kathleen Knutson

Original Assignee

Epizyme, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-04-13

Filing date

2012-04-13

Publication date

2019-02-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46045109&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3150580(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-04-13 Application filed by Epizyme, Inc. filed Critical Epizyme, Inc.

2019-02-11 Publication of LT3150580T publication Critical patent/LT3150580T/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Peptides Or Proteins (AREA)
Pyridine Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Enzymes And Modification Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

LTEP16172386.1T 2011-04-13 2012-04-13 Aril- arba heteroaril-pakeistieji benzeno junginiai LT3150580T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161474821P	2011-04-13	2011-04-13
US201161499595P	2011-06-21	2011-06-21

Publications (1)

Publication Number	Publication Date
LT3150580T true LT3150580T (lt)	2019-02-11

Family

ID=46045109

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
LTEP12719529.5T LT2697199T (lt)	2011-04-13	2012-04-13	Aril- arba heteroaril- pakeistieji benzeno junginiai
LTEP16172386.1T LT3150580T (lt)	2011-04-13	2012-04-13	Aril- arba heteroaril-pakeistieji benzeno junginiai
LTEP18200713.8T LT3486234T (lt)	2011-04-13	2012-04-13	Arilu arba heteroarilu pakeisti benzeno junginiai
LTEP21175920.4T LT3943485T (lt)	2011-04-13	2012-04-13	Arilu arba heteroarilu pakeisti benzeno junginiai

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LTEP12719529.5T LT2697199T (lt)	2011-04-13	2012-04-13	Aril- arba heteroaril- pakeistieji benzeno junginiai

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
LTEP18200713.8T LT3486234T (lt)	2011-04-13	2012-04-13	Arilu arba heteroarilu pakeisti benzeno junginiai
LTEP21175920.4T LT3943485T (lt)	2011-04-13	2012-04-13	Arilu arba heteroarilu pakeisti benzeno junginiai

Country Status (35)

Country	Link
US (15)	US8410088B2 (lt)
EP (5)	EP2697199B1 (lt)
JP (6)	JP5933686B2 (lt)
KR (8)	KR20230134128A (lt)
CN (2)	CN104080769B (lt)
AR (1)	AR086008A1 (lt)
AU (1)	AU2012242595B2 (lt)
BR (2)	BR112013026324B1 (lt)
CA (2)	CA3086473A1 (lt)
CL (1)	CL2013002898A1 (lt)
CY (3)	CY1117986T1 (lt)
DK (4)	DK3943485T3 (lt)
ES (4)	ES2589555T3 (lt)
FI (1)	FI3943485T3 (lt)
HR (3)	HRP20161115T1 (lt)
HU (4)	HUE028837T2 (lt)
IL (5)	IL228745A (lt)
JO (2)	JO3438B1 (lt)
LT (4)	LT2697199T (lt)
ME (1)	ME02500B (lt)
MX (3)	MX384521B (lt)
MY (1)	MY166171A (lt)
NZ (3)	NZ717119A (lt)
PE (1)	PE20140863A1 (lt)
PH (2)	PH12016502132B1 (lt)
PL (4)	PL2697199T3 (lt)
PT (4)	PT3150580T (lt)
RS (3)	RS55113B1 (lt)
RU (1)	RU2632193C2 (lt)
SG (1)	SG194447A1 (lt)
SI (4)	SI3486234T1 (lt)
SM (3)	SMT201900050T1 (lt)
TW (1)	TWI529162B (lt)
WO (1)	WO2012142504A1 (lt)
ZA (1)	ZA201307539B (lt)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2011160206A1 (en)	2010-06-23	2011-12-29	Morin Ryan D	Biomarkers for non-hodgkin lymphomas and uses thereof
AU2011298987B2 (en)	2010-09-10	2017-09-28	Epizyme, Inc.	Inhibitors of human EZH2, and methods of use thereof
US9175331B2 (en)	2010-09-10	2015-11-03	Epizyme, Inc.	Inhibitors of human EZH2, and methods of use thereof
TWI598336B (zh)	2011-04-13	2017-09-11	雅酶股份有限公司	經取代之苯化合物
JO3438B1 (ar) *	2011-04-13	2019-10-20	Epizyme Inc	مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
CA2850570A1 (en)	2011-09-30	2013-04-04	Glaxosmithkline Llc	Methods of treating cancer
WO2013075084A1 (en)	2011-11-18	2013-05-23	Constellation Pharmaceuticals	Modulators of methyl modifying enzymes, compositions and uses thereof
CA2862289C (en)	2012-02-10	2019-11-26	Constellation Pharmaceuticals, Inc.	Modulators of methyl modifying enzymes, compositions and uses thereof
ES2718900T3 (es) *	2012-03-12	2019-07-05	Epizyme Inc	Inhibidores de EZH2 humana y métodos de uso de los mismos
BR112014025508B1 (pt)	2012-04-13	2020-11-17	Eisai R&D Management Co., Ltd.	forma de sal de um inibidor de histona metiltransferase ezh2 humana
MX367793B (es) *	2012-04-13	2019-09-06	Epizyme Inc	Terapia de combinación para tratar cáncer.
US9562041B2 (en)	2012-05-16	2017-02-07	Glaxosmithkline Llc	Enhancer of zeste homolog 2 inhibitors
JP6254169B2 (ja) *	2012-09-28	2017-12-27	ファイザー・インク	ベンズアミドおよびヘテロベンズアミド化合物
JP6461803B2 (ja)	2012-10-15	2019-01-30	エピザイム，インコーポレイティド	置換ベンゼン化合物
US9688665B2 (en) *	2012-10-15	2017-06-27	Epizyme, Inc.	Methods of treating cancer
JP2016503009A (ja) *	2012-12-13	2016-02-01	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅＬＬＣ	Ｚｅｓｔｅホモログ２エンハンサー阻害剤
EP2934531A4 (en) *	2012-12-19	2016-06-15	Glaxosmithkline Llc	COMBINATION
US9701666B2 (en)	2012-12-21	2017-07-11	Epizyme, Inc.	1,4-pyridone bicyclic heteroaryl compounds
UA111305C2 (uk)	2012-12-21	2016-04-11	Пфайзер Інк.	Конденсовані лактами арилу та гетероарилу
EP2935214B1 (en) *	2012-12-21	2019-02-20	Epizyme, Inc.	1,4-pyridone compounds
PL2953941T3 (pl) *	2013-02-11	2017-11-30	Constellation Pharmaceuticals, Inc.	Modulatory enzymów modyfikujących metyl, ich kompozycje i zastosowania
WO2014153235A2 (en)	2013-03-14	2014-09-25	Epizyme, Inc.	Arginine methyltransferase inhibitors and uses thereof
US9133189B2 (en)	2013-03-14	2015-09-15	Epizyme, Inc.	Arginine methyltransferase inhibitors and uses thereof
US8952026B2 (en)	2013-03-14	2015-02-10	Epizyme, Inc.	PRMT1 inhibitors and uses thereof
WO2014153208A1 (en)	2013-03-14	2014-09-25	Epizyme, Inc.	Arginine methyltransferase inhibitors and uses thereof
SG11201506972PA (en)	2013-03-14	2015-10-29	Epizyme Inc	Arginine methyltransferase inhibitors and uses thereof
US9120757B2 (en)	2013-03-14	2015-09-01	Epizyme, Inc.	Arginine methyltransferase inhibitors and uses thereof
EP2970133B1 (en)	2013-03-14	2018-10-24	Epizyme, Inc.	Pyrazole derivatives as prmt1 inhibitors and uses thereof
WO2014144659A1 (en)	2013-03-14	2014-09-18	Epizyme, Inc.	Pyrazole derivatives as prmt1 inhibitors and uses thereof
JP2016514164A (ja)	2013-03-14	2016-05-19	エピザイム，インコーポレイティド	アルギニンメチルトランスフェラーゼ阻害剤としてのピラゾール誘導体およびその使用
WO2014153030A2 (en)	2013-03-14	2014-09-25	Genentech, Inc.	Methods of treating cancer and preventing cancer drug resistance
US9365527B2 (en)	2013-03-14	2016-06-14	Epizyme, Inc.	Arginine methyltransferase inhibitors and uses thereof
EP2970281A4 (en)	2013-03-15	2016-08-03	Epizyme Inc	SUBSTITUTED BENZOL COMPOUNDS
US9243001B2 (en)	2013-03-15	2016-01-26	Epizyme, Inc.	Substituted benzene compounds
WO2014151142A1 (en)	2013-03-15	2014-09-25	Constellation Pharmaceuticals, Inc.	Modulators of methyl modifying enzymes, compositions and uses thereof
NZ630205A (en)	2013-04-30	2017-03-31	Glaxosmithkline Intellectual Property (No 2) Ltd	Enhancer of zeste homolog 2 inhibitors
EP3004096A1 (en) *	2013-06-06	2016-04-13	Glaxosmithkline Intellectual Property (No. 2) Limited	Enhancer of zeste homolog 2 inhibitors
ES2640386T3 (es)	2013-07-10	2017-11-02	Glaxosmithkline Intellectual Property (No. 2) Limited	Potenciador de inhibidores del homólogo Zeste 2
WO2015010049A1 (en) *	2013-07-19	2015-01-22	Epizyme, Inc.	Substituted benzene compounds
WO2015010078A2 (en)	2013-07-19	2015-01-22	Epizyme, Inc.	Substituted 6,5-fused bicyclic heteroaryl compounds
WO2015023915A1 (en)	2013-08-15	2015-02-19	Constellation Pharmaceuticals, Inc.	Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
EA038869B1 (ru) *	2013-10-16	2021-10-29	Эпизим, Инк.	Кристаллические формы гидрохлорида n-((4,6-диметил-2-оксо-1,2-дигидропиридин-3-ил)метил)-5-(этил(тетрагидро-2h-пиран-4-ил)амино)-4-метил-4'-(морфолинометил)-[1,1'-бифенил]-3-карбоксамида, фармацевтические композиции на их основе и способы их применения
US9738630B2 (en)	2013-11-19	2017-08-22	Bristol-Myers Squibb Company	Inhibitors of lysine methyl transferase
US9822103B2 (en)	2013-11-22	2017-11-21	Bristol-Myers Squibb Company	Inhibitors of lysine methyl transferase
ES2863996T3 (es)	2013-12-06	2021-10-13	Epizyme Inc	Terapia de combinación para el tratamiento del cáncer
CN105037360B (zh) *	2014-04-28	2016-08-17	四川大学	吡啶酮衍生物及其制备方法和用途
LT3157527T (lt)	2014-06-17	2023-07-25	Epizyme, Inc.	Ezh2 inhibitoriai, skirti limfomos gydymui
BR112016029612B1 (pt)	2014-06-17	2021-01-19	Pfizer Inc.	compostos de di-hidroisoquinolinona substituídos
US20170217941A1 (en)	2014-06-25	2017-08-03	Epizyme, Inc.	Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
KR20170042779A (ko)	2014-08-21	2017-04-19	베링거 인겔하임 인터내셔날 게엠베하	Mdm2-p53 억제제로서의 신규 스피로[3h-인돌-3,2'-피롤리딘]-2(1h)-온 화합물 및 유도체
IL289947B2 (en)	2014-10-16	2024-06-01	Epizyme Inc	Method for treating cancer
CN107148419A (zh) *	2014-10-28	2017-09-08	葛兰素史密斯克莱知识产权（第2 号）有限公司	Zeste增强子同源物2抑制剂
WO2016073956A1 (en)	2014-11-06	2016-05-12	Dana-Farber Cancer Institute, Inc.	Ezh2 inhibitors and uses thereof
US10786511B2 (en)	2014-11-17	2020-09-29	Epizyme, Inc.	Method for treating cancer
AR102767A1 (es)	2014-12-05	2017-03-22	Lilly Co Eli	Inhibidores de ezh2
WO2016172199A1 (en) *	2015-04-20	2016-10-27	Epizyme, Inc.	Combination therapy for treating cancer
WO2016201328A1 (en)	2015-06-10	2016-12-15	Epizyme, Inc.	Ezh2 inhibitors for treating lymphoma
UY36758A (es) *	2015-06-30	2016-12-30	Glaxosmithkline Ip No 2 Ltd	Inhibidores del potenciador del homólogo zeste 2
SG10201909199PA (en)	2015-08-24	2019-11-28	Epizyme Inc	Method for treating cancer
TW201718598A (zh)	2015-08-27	2017-06-01	美國禮來大藥廠	Ｅｚｈ２抑制劑
WO2017040190A1 (en)	2015-08-28	2017-03-09	Constellation Pharmaceuticals, Inc.	Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
CA3000983A1 (en) *	2015-10-06	2017-04-13	The Regents Of The University Of Colorado, A Body Corporate	Method of treating medulloblastoma with an ezh2 inhibitor
PL3359542T3 (pl)	2015-10-09	2021-09-20	Boehringer Ingelheim International Gmbh	Związki i pochodne spiro[3h-indolo-3,2’-pirolidyno]-2(1h)-onowe jako inhibitory mdm2-p53
JP2018532761A (ja) *	2015-11-06	2018-11-08	エピザイム，インコーポレイティド	Ｅｚｈ２阻害剤を用いた癌の処置のための小児投与
JP6828229B2 (ja)	2015-11-19	2021-02-10	ジエンスヘンルイメデイシンカンパニーリミテッドＪｉａｎｇｓｕＨｅｎｇｒｕｉＭｅｄｉｃｉｎｅＣｏ．，Ｌｔｄ．	ベンゾフラン誘導体、その製造方法および医薬におけるその使用
CN105440023A (zh) *	2015-12-10	2016-03-30	江苏理工学院	Epz-6438的合成方法
TWI773657B (zh)	2015-12-18	2022-08-11	美商亞德利克斯公司	作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
US12084472B2 (en)	2015-12-18	2024-09-10	Ardelyx, Inc.	Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
CA3011186A1 (en)	2016-01-29	2017-08-03	Epizyme, Inc.	Combination therapy for treating cancer
CN109195593A (zh)	2016-03-15	2019-01-11	奥莱松基因组股份有限公司	用于治疗实体瘤的lsd1抑制剂的组合
WO2017174023A1 (zh) *	2016-04-08	2017-10-12	南京明德新药研发股份有限公司	作为ezh2抑制剂的联苯化合物
WO2017184999A1 (en) *	2016-04-22	2017-10-26	Dana-Farber Cancer Institute, Inc.	Ezh2 inhibitors and uses thereof
US10987353B2 (en)	2016-05-04	2021-04-27	The Wistar Institute Of Anatomy And Biology	Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and platinum-based antineoplastic drugs
EP3452483B1 (en)	2016-05-05	2020-04-01	GlaxoSmithKline Intellectual Property (No. 2) Limited	Enhancer of zeste homolog 2 inhibitors
WO2017210395A1 (en) *	2016-06-01	2017-12-07	Epizyme, Inc.	Use of ezh2 inhibitors for treating cancer
MA45406A (fr)	2016-06-17	2019-04-24	Epizyme Inc	Inhibiteurs d'ezh2 pour traiter le cancer
US10457640B2 (en)	2016-10-19	2019-10-29	Constellation Pharmaceuticals, Inc.	Synthesis of inhibitors of EZH2
EP3548032A2 (en)	2016-12-02	2019-10-09	Epizyme, Inc.	Combination therapy for treating cancer
US11191741B2 (en)	2016-12-24	2021-12-07	Arvinas Operations, Inc.	Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
CN108314677B (zh)	2017-01-17	2020-06-30	安徽中科拓苒药物科学研究有限公司	一种ezh2抑制剂及其用途
EP3572095A4 (en) *	2017-01-19	2020-11-18	Daiichi Sankyo Company, Limited	Pharmaceutical composition used for treatment of htlv-1-associated myelopathy
WO2018137639A1 (zh)	2017-01-25	2018-08-02	恩瑞生物医药科技（上海）有限公司	一种组蛋白甲基转移酶ezh2抑制剂、其制备方法及其医药用途
US10266542B2 (en)	2017-03-15	2019-04-23	Mirati Therapeutics, Inc.	EZH2 inhibitors
US11642346B2 (en)	2017-03-31	2023-05-09	Epizyme, Inc.	Combination therapy for treating cancer
JP2020517618A (ja) *	2017-04-21	2020-06-18	エピザイム，インコーポレイティド	Ｅｈｍｔ２阻害剤との併用療法
CN109937200B (zh)	2017-05-18	2020-09-11	江苏恒瑞医药股份有限公司	一种苯并呋喃类衍生物游离碱的晶型及制备方法
US11602529B2 (en)	2017-06-02	2023-03-14	Epizyme, Inc.	Use of EZH2 inhibitors for treating cancer
WO2018231973A1 (en)	2017-06-13	2018-12-20	Epizyme, Inc.	Inhibitors of ezh2 and methods of use thereof
EP3678663A4 (en) *	2017-09-05	2021-06-02	Epizyme, Inc.	POLYTHERAPY FOR CANCER TREATMENT
CA3082287C (en)	2017-11-14	2023-02-28	Pfizer Inc.	Ezh2 inhibitor combination therapies
HUE059536T2 (hu)	2018-01-31	2022-11-28	Mirati Therapeutics Inc	PRC2-inhibitorok
CN108640842B (zh) *	2018-04-04	2021-06-04	大连九信精细化工有限公司	一种2-溴-5-氟硝基苯的合成方法
CN112449642A (zh) *	2018-06-07	2021-03-05	默沙东公司	用于制备舒更葡糖的方法
CN112399857A (zh)	2018-07-09	2021-02-23	盲人庇护基金会	Prc2亚单位的抑制治疗眼失调
CN113480525B (zh) *	2018-07-27	2024-02-27	苏州信诺维医药科技股份有限公司	多取代苯环化合物、制备方法及其用途
KR102689665B1 (ko)	2019-02-19	2024-07-31	한미약품 주식회사	신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도
US12473298B2 (en)	2019-03-25	2025-11-18	Shanghai Synergy Pharmaceutical Sciences Co., Ltd.	Amide compounds, preparation method therefor, and use thereof in the medical field
US12421228B2 (en)	2019-04-22	2025-09-23	Mirati Therapeutics, Inc.	Naphthyridine derivatives as PRC2 inhibitors
CN114423463B (zh)	2019-05-06	2025-09-26	西奈山伊坎医学院	作为hpk1的降解剂的异双功能化合物
CN114269748A (zh)	2019-06-05	2022-04-01	米拉蒂医疗股份有限公司	作为用于治疗癌症的PRC2抑制剂的咪唑并[1,2-c]嘧啶衍生物
EP4003532B1 (en)	2019-07-24	2024-09-04	Constellation Pharmaceuticals, Inc.	Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
KR20220066892A (ko)	2019-08-22	2022-05-24	주노 쎄러퓨티크스 인코퍼레이티드	Ｔ 세포 요법 및 제스트 동족체 2의 인핸서 (ｅｚｈ2) 억제제의 병용 요법 및 관련 방법
CN115551842B (zh) *	2020-06-08	2024-04-23	南京明德新药研发有限公司	联苯类化合物
PE20230732A1 (es)	2020-08-13	2023-05-03	Hanmi Pharmaceutical Co Ltd	Derivados de dioxoloisoquinolinona novedosos y uso de los mismos
EP4230625A4 (en)	2020-10-13	2024-10-16	Evopoint Biosciences Co., Ltd.	CRYSTAL FORM OF MULTI-SUBSTITUTED BENZENE RING COMPOUND MALEATE AND PRODUCTION PROCESS AND USE THEREOF
CN114907299B (zh) *	2021-02-08	2024-06-25	上海医药工业研究院	他泽司他关键中间体的盐型、其制备方法及其中间体
CN114907300B (zh) *	2021-02-08	2024-05-28	上海医药工业研究院	他泽司他关键中间体的制备方法及其中间体
CN113292489B (zh) *	2021-06-16	2022-08-30	泓博智源(开原)药业有限公司	二氯代二烷基烟腈的制备方法
CN113527275A (zh) *	2021-07-20	2021-10-22	成都师范学院	一种sklb1039化合物及其制备方法和应用
CN113582863B (zh) *	2021-08-19	2023-05-26	沈阳农业大学	一种氨乙基联苯类化合物及其制备方法和用途
KR20230081459A (ko)	2021-11-30	2023-06-07	엘젠테라퓨틱스 주식회사	헤테로사이클릭이 치환된 신규한 3-페닐피리딘과 4-페닐피리딘 유도체 및 이의 용도
WO2023111810A1 (en)	2021-12-14	2023-06-22	Pfizer Inc.	Combination therapies and uses for treating cancer
US20250276079A1 (en)	2022-04-27	2025-09-04	Daiichi Sankyo Company, Limited	COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH EZH1 and/or EZH2 INHIBITOR
CA3258325A1 (en)	2022-06-13	2023-12-21	Treeline Biosciences, Inc.	BIFUNCTIONAL QUINOLONE DEGRADING AGENTS BCL6
KR20250023481A (ko)	2022-06-13	2025-02-18	트리라인 바이오사이언시스, 인크.	1,8-나프티리딘-2-온 이종이작용성 bcl6 분해제
CN115197202B (zh) *	2022-07-15	2024-01-26	四川大学	一种ezh2共价抑制剂及其制备方法和应用

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPH0733729A (ja)	1993-07-26	1995-02-03	Kirin Brewery Co Ltd	Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法
HUT74450A (en) *	1993-12-27	1996-12-30	Eisai Co Ltd	Anthranilic acid derivative and pharmaceutical compns. contg. such compds.
DE19516776A1 (de)	1995-05-10	1996-11-14	Boehringer Ingelheim Int	Chromatin-Regulatorgene
US5741819A (en)	1995-06-07	1998-04-21	3-Dimensional Pharmaceuticals, Inc.	Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
US5763263A (en)	1995-11-27	1998-06-09	Dehlinger; Peter J.	Method and apparatus for producing position addressable combinatorial libraries
JP3906935B2 (ja)	1995-12-18	2007-04-18	杏林製薬株式会社	Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
JP2002525352A (ja)	1998-09-30	2002-08-13	ザ、プロクター、エンド、ギャンブル、カンパニー	２−置換ケトアミド
UA71587C2 (uk)	1998-11-10	2004-12-15	Шерінг Акцієнгезелльшафт	Аміди антранілової кислоти та їхнє застосування як лікарських засобів
US6710058B2 (en)	2000-11-06	2004-03-23	Bristol-Myers Squibb Pharma Company	Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
KR100828982B1 (ko)	2000-12-28	2008-05-14	시오노기세이야쿠가부시키가이샤	칸나비노이드 2형 수용체 친화 작용을 갖는 피리돈 유도체
EP1363702A4 (en) *	2001-01-30	2007-08-22	Cytopia Pty Ltd	PROCESS FOR INHIBITING KINASES
US7700293B2 (en)	2001-08-02	2010-04-20	The Regents Of The University Of Michigan	Expression profile of prostate cancer
JP5082033B2 (ja) *	2001-12-21	2012-11-28	エグゼリクシスパテントカンパニーエルエルシー	Ｌｘｒのモジュレーター
DE60329981D1 (de)	2002-02-19	2009-12-24	Shionogi & Co	Antipruriginosa
TW200306155A (en)	2002-03-19	2003-11-16	Du Pont	Benzamides and advantageous compositions thereof for use as fungicides
BRPI0317740B8 (pt)	2002-12-27	2021-05-25	Sucampo Ag	uso do composto 13,14-diidro-15-ceto-16,16-diflúorprostaglandina e1
CN103265477B (zh)	2003-02-26	2017-01-11	苏根公司	作为蛋白激酶抑制剂的氨基杂芳基化合物
WO2005014599A1 (en) *	2003-06-04	2005-02-17	Cellular Genomics, Inc.	Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
US7442685B2 (en)	2003-06-13	2008-10-28	The University Of North Carolina At Chapel Hill	DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
JP4869068B2 (ja)	2003-06-19	2012-02-01	スミスクラインビーチャムコーポレーション	化合物
PT1663978E (pt)	2003-07-23	2008-02-15	Bayer Pharmaceuticals Corp	Omega-carboxiaril difenil ureia substituída por flúor para o tratamento e a prevenção de doenças e estados patológicos
CA2535806C (en)	2003-08-26	2009-02-17	Aton Pharma, Inc.	The use of hdac inhibitors for the treatment of cancer
US20050059682A1 (en)	2003-09-12	2005-03-17	Supergen, Inc., A Delaware Corporation	Compositions and methods for treatment of cancer
WO2005094816A1 (en)	2004-03-11	2005-10-13	Actelion Pharmaceuticals Ltd	Indol-1-yl-acetic acid derivatives
CN1286973C (zh)	2004-04-12	2006-11-29	上海第二医科大学附属瑞金医院	一种组蛋白甲基转移酶及其制备方法
DE602005017781D1 (de)	2004-06-01	2009-12-31	Univ North Carolina	Rekonstituierter histon-methyltransferase-komplex und verfahren zur identifizierung von modulatoren dafür
JO2787B1 (en)	2005-04-27	2014-03-15	امجين إنك,	Alternative amide derivatives and methods of use
US7923219B2 (en)	2005-06-02	2011-04-12	The University Of North Carolina At Chapel Hill	Ubiquitin E3 ligase
FR2889526B1 (fr)	2005-08-04	2012-02-17	Aventis Pharma Sa	7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
US8710233B2 (en)	2005-10-19	2014-04-29	Gruenenthal Gmbh	Vanilloid receptor ligands and use thereof for the production of pharmaceutical preparations
ATE510822T1 (de)	2005-10-21	2011-06-15	Merck Sharp & Dohme	Kaliumkanalinhibitoren
US20090203057A1 (en)	2005-10-28	2009-08-13	Yi Zhang	Protein demethylases comprising a jmjc domain
WO2007072225A2 (en)	2005-12-01	2007-06-28	Medical Prognosis Institute	Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2007070818A1 (en)	2005-12-14	2007-06-21	Bristol-Myers Squibb Company	Six-membered heterocycles useful as serine protease inhibitors
EP2730661A1 (en)	2006-01-20	2014-05-14	The University of North Carolina at Chapel Hill	Diagnostic and therapeutic targets for leukemia
EP2018166A2 (en)	2006-05-15	2009-01-28	Irm Llc	Terephthalamate compounds and compositions, and their use as hiv integrase inhibitors
WO2007136592A2 (en)	2006-05-18	2007-11-29	Amphora Discovery Corporation	2-0x0-l,2-dihydr0quin0line derivatives, compositions, and uses thereof as antiproliferative agents
WO2008108825A2 (en)	2006-10-10	2008-09-12	Burnham Institute For Medical Research	Neuroprotective compositions and methods
MX2009008531A (es)	2007-02-16	2009-08-26	Amgen Inc	Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
EP2137158A4 (en)	2007-02-28	2012-04-18	Methylgene Inc	LOW-MOLECULAR INHIBITORS OF PROTEINARGININE METHYLTRANSFERASES (PRMTS)
WO2008109534A1 (en) *	2007-03-02	2008-09-12	Mdrna, Inc.	Nucleic acid compounds for inhibiting ezh2 gene expression and uses thereof
WO2008113006A1 (en)	2007-03-14	2008-09-18	Xenon Pharmaceuticals Inc.	Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
DE102007017884A1 (de)	2007-04-13	2008-10-16	Grünethal GmbH	Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
WO2009006577A2 (en) *	2007-07-03	2009-01-08	The Regents Of The University Of Michigan	Compositions and methods for inhibiting ezh2
EP2170834B1 (en)	2007-07-16	2014-01-08	AbbVie Inc.	Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases
WO2009058298A1 (en) *	2007-10-31	2009-05-07	Merck & Co., Inc.	P2x3, receptor antagonists for treatment of pain
BRPI0821227A2 (pt)	2007-12-19	2015-06-16	Cancer Rec Tech Ltd	Composto, composição farmacêutica, método para preparar a mesma, uso de um composto, método para tratar uma doença ou distúrbio, para inibir função de raf e para inibir proliferação celular, inibir progressão do ciclo celular, promover apoptose, ou uma combinação de um ou mais dos mesmos
KR101608096B1 (ko)	2008-01-23	2016-03-31	브리스톨-마이어스 스큅 컴퍼니	４-피리디논 화합물 및 암을 위한 그의 용도
WO2009124137A2 (en)	2008-04-01	2009-10-08	Mount Sinai School Of Medicine Of New York University	Method of suppressing gene transcription through histone lysine methylation
US20100113415A1 (en)	2008-05-29	2010-05-06	Rajapakse Hemaka A	Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
UY31982A (es) *	2008-07-16	2010-02-26	Boehringer Ingelheim Int	Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas
AU2009279616A1 (en)	2008-08-08	2010-02-11	New York Blood Center	Small molecule inhibitors of retroviral assembly and maturation
FR2934995B1 (fr)	2008-08-14	2010-08-27	Sanofi Aventis	Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique
CA2756152A1 (fr) *	2009-03-24	2010-09-30	Sanofi	Derives d'azacarbolines 9h-pyrrolo[2,3-b:5,4-c']dipyridine, leur preparation et leur utilisation therapeutique
EP2411007A4 (en)	2009-03-27	2012-12-05	Uab Research Foundation	MODULATION OF IRES-MEDIATED TRANSLATION
US20110021362A1 (en)	2009-07-20	2011-01-27	Constellation Pharmaceuticals	Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
US8329149B2 (en)	2009-12-30	2012-12-11	Avon Products, Inc.	Topical lightening composition and uses thereof
ES2528269T3 (es) *	2010-05-07	2015-02-06	Glaxosmithkline Llc	Azaindazoles
EP2566328B1 (en) *	2010-05-07	2015-03-04	GlaxoSmithKline LLC	Indazoles
EP2566327B1 (en) *	2010-05-07	2017-03-29	Glaxosmithkline LLC	Indoles
WO2011160206A1 (en)	2010-06-23	2011-12-29	Morin Ryan D	Biomarkers for non-hodgkin lymphomas and uses thereof
AU2011298987B2 (en)	2010-09-10	2017-09-28	Epizyme, Inc.	Inhibitors of human EZH2, and methods of use thereof
US9175331B2 (en)	2010-09-10	2015-11-03	Epizyme, Inc.	Inhibitors of human EZH2, and methods of use thereof
US20130310379A1 (en)	2010-11-19	2013-11-21	Constellation Pharmaceuticals	Modulators of methyl modifying enzymes, compositions and uses thereof
JP5908493B2 (ja)	2010-12-01	2016-04-26	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅＬＬＣ	インドール
RU2013130253A (ru)	2010-12-03	2015-01-10	Эпизайм, Инк.	7-деазапуриновые регуляторы метилтрансферазы гистонов и способы их применения
EP2681216B1 (en)	2011-02-28	2017-09-27	Epizyme, Inc.	Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) *	2011-04-13	2019-10-20	Epizyme Inc	مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TWI598336B (zh)	2011-04-13	2017-09-11	雅酶股份有限公司	經取代之苯化合物
CA2850570A1 (en)	2011-09-30	2013-04-04	Glaxosmithkline Llc	Methods of treating cancer
ES2718900T3 (es) *	2012-03-12	2019-07-05	Epizyme Inc	Inhibidores de EZH2 humana y métodos de uso de los mismos
BR112014025508B1 (pt)	2012-04-13	2020-11-17	Eisai R&D Management Co., Ltd.	forma de sal de um inibidor de histona metiltransferase ezh2 humana
MX367793B (es)	2012-04-13	2019-09-06	Epizyme Inc	Terapia de combinación para tratar cáncer.
US9562041B2 (en)	2012-05-16	2017-02-07	Glaxosmithkline Llc	Enhancer of zeste homolog 2 inhibitors
JP6461803B2 (ja)	2012-10-15	2019-01-30	エピザイム，インコーポレイティド	置換ベンゼン化合物
US9688665B2 (en)	2012-10-15	2017-06-27	Epizyme, Inc.	Methods of treating cancer
US9701666B2 (en)	2012-12-21	2017-07-11	Epizyme, Inc.	1,4-pyridone bicyclic heteroaryl compounds
EP2970306A4 (en)	2013-03-15	2016-08-03	Epizyme Inc	SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS
US9045477B2 (en)	2013-03-15	2015-06-02	Epizyme, Inc.	Substituted 6,5-fused bicyclic heteroaryl compounds
US9243001B2 (en)	2013-03-15	2016-01-26	Epizyme, Inc.	Substituted benzene compounds
WO2015010078A2 (en)	2013-07-19	2015-01-22	Epizyme, Inc.	Substituted 6,5-fused bicyclic heteroaryl compounds
WO2015010049A1 (en)	2013-07-19	2015-01-22	Epizyme, Inc.	Substituted benzene compounds
EA038869B1 (ru)	2013-10-16	2021-10-29	Эпизим, Инк.	Кристаллические формы гидрохлорида n-((4,6-диметил-2-оксо-1,2-дигидропиридин-3-ил)метил)-5-(этил(тетрагидро-2h-пиран-4-ил)амино)-4-метил-4'-(морфолинометил)-[1,1'-бифенил]-3-карбоксамида, фармацевтические композиции на их основе и способы их применения
ES2863996T3 (es)	2013-12-06	2021-10-13	Epizyme Inc	Terapia de combinación para el tratamiento del cáncer
LT3157527T (lt)	2014-06-17	2023-07-25	Epizyme, Inc.	Ezh2 inhibitoriai, skirti limfomos gydymui
IL289947B2 (en)	2014-10-16	2024-06-01	Epizyme Inc	Method for treating cancer
US10786511B2 (en)	2014-11-17	2020-09-29	Epizyme, Inc.	Method for treating cancer
WO2016172199A1 (en)	2015-04-20	2016-10-27	Epizyme, Inc.	Combination therapy for treating cancer
WO2016201328A1 (en)	2015-06-10	2016-12-15	Epizyme, Inc.	Ezh2 inhibitors for treating lymphoma
SG10201909199PA (en)	2015-08-24	2019-11-28	Epizyme Inc	Method for treating cancer
CN108349958B (zh)	2015-09-25	2022-02-15	Epizyme股份有限公司	用ezh2抑制剂治疗mrto/sccoht的方法
EP3371601A1 (en)	2015-11-05	2018-09-12	Epizyme Inc	Flow cytometry for monitoring histone h3 methylation status
CA3007492A1 (en)	2015-12-07	2017-06-15	Epizyme, Inc.	Inhibitors of ezh2 and methods of use thereof
CA3011186A1 (en)	2016-01-29	2017-08-03	Epizyme, Inc.	Combination therapy for treating cancer
US20190038633A1 (en)	2016-02-08	2019-02-07	Epizyme, Inc.	Methods of treating cancer
WO2017210395A1 (en)	2016-06-01	2017-12-07	Epizyme, Inc.	Use of ezh2 inhibitors for treating cancer
MA45406A (fr)	2016-06-17	2019-04-24	Epizyme Inc	Inhibiteurs d'ezh2 pour traiter le cancer
EP3548032A2 (en)	2016-12-02	2019-10-09	Epizyme, Inc.	Combination therapy for treating cancer
AU2018217139A1 (en)	2017-02-02	2019-08-22	Epizyme, Inc.	Cancer treatment modalities
US11642346B2 (en)	2017-03-31	2023-05-09	Epizyme, Inc.	Combination therapy for treating cancer
US11602529B2 (en)	2017-06-02	2023-03-14	Epizyme, Inc.	Use of EZH2 inhibitors for treating cancer
WO2018231973A1 (en)	2017-06-13	2018-12-20	Epizyme, Inc.	Inhibitors of ezh2 and methods of use thereof
EP3678663A4 (en)	2017-09-05	2021-06-02	Epizyme, Inc.	POLYTHERAPY FOR CANCER TREATMENT
BR112022012258A2 (pt)	2019-12-20	2022-08-30	Epizyme Inc	Sal cristalino de bromidreto de um inibidor de ezh2, sua preparação e composição farmacêutica útil para o tratamento de câncer
WO2021243060A1 (en)	2020-05-28	2021-12-02	Epizyme, Inc.	Use of ezh2 inhibitors for treating cancer

2011
- 2011-04-13 JO JOP/2018/0104A patent/JO3438B1/ar active
2012
- 2012-04-10 JO JOP/2012/0087A patent/JO3363B1/ar active
- 2012-04-12 TW TW101112994A patent/TWI529162B/zh active
- 2012-04-13 KR KR1020237027131A patent/KR20230134128A/ko not_active Ceased
- 2012-04-13 PT PT16172386T patent/PT3150580T/pt unknown
- 2012-04-13 CN CN201280029207.0A patent/CN104080769B/zh active Active
- 2012-04-13 SI SI201231941T patent/SI3486234T1/sl unknown
- 2012-04-13 US US13/447,007 patent/US8410088B2/en active Active
- 2012-04-13 HR HRP20161115TT patent/HRP20161115T1/hr unknown
- 2012-04-13 KR KR1020197005890A patent/KR102032303B1/ko active Active
- 2012-04-13 PT PT211759204T patent/PT3943485T/pt unknown
- 2012-04-13 PL PL12719529.5T patent/PL2697199T3/pl unknown
- 2012-04-13 EP EP12719529.5A patent/EP2697199B1/en active Active
- 2012-04-13 KR KR1020207024969A patent/KR102308488B1/ko active Active
- 2012-04-13 LT LTEP12719529.5T patent/LT2697199T/lt unknown
- 2012-04-13 PL PL18200713T patent/PL3486234T3/pl unknown
- 2012-04-13 HU HUE12719529A patent/HUE028837T2/en unknown
- 2012-04-13 PH PH1/2016/502132A patent/PH12016502132B1/en unknown
- 2012-04-13 FI FIEP21175920.4T patent/FI3943485T3/fi active
- 2012-04-13 DK DK21175920.4T patent/DK3943485T3/da active
- 2012-04-13 NZ NZ717119A patent/NZ717119A/en unknown
- 2012-04-13 EP EP23217912.7A patent/EP4360712A3/en active Pending
- 2012-04-13 PE PE2013002280A patent/PE20140863A1/es active IP Right Grant
- 2012-04-13 HR HRP20211297TT patent/HRP20211297T8/hr unknown
- 2012-04-13 ES ES12719529.5T patent/ES2589555T3/es active Active
- 2012-04-13 ES ES21175920T patent/ES2973868T3/es active Active
- 2012-04-13 AU AU2012242595A patent/AU2012242595B2/en active Active
- 2012-04-13 SM SM20190050T patent/SMT201900050T1/it unknown
- 2012-04-13 PT PT127195295T patent/PT2697199T/pt unknown
- 2012-04-13 RS RS20160706A patent/RS55113B1/sr unknown
- 2012-04-13 CN CN201710425075.8A patent/CN107311921B/zh active Active
- 2012-04-13 PL PL16172386T patent/PL3150580T3/pl unknown
- 2012-04-13 PT PT182007138T patent/PT3486234T/pt unknown
- 2012-04-13 BR BR112013026324-5A patent/BR112013026324B1/pt active IP Right Grant
- 2012-04-13 EP EP18200713.8A patent/EP3486234B1/en active Active
- 2012-04-13 DK DK16172386.1T patent/DK3150580T3/en active
- 2012-04-13 MY MYPI2013003694A patent/MY166171A/en unknown
- 2012-04-13 NZ NZ734744A patent/NZ734744A/en unknown
- 2012-04-13 SI SI201230695A patent/SI2697199T1/sl unknown
- 2012-04-13 DK DK12719529.5T patent/DK2697199T3/en active
- 2012-04-13 RS RS20211082A patent/RS62279B1/sr unknown
- 2012-04-13 WO PCT/US2012/033648 patent/WO2012142504A1/en not_active Ceased
- 2012-04-13 SM SM20210503T patent/SMT202100503T1/it unknown
- 2012-04-13 EP EP21175920.4A patent/EP3943485B1/en active Active
- 2012-04-13 NZ NZ616298A patent/NZ616298A/en unknown
- 2012-04-13 RU RU2013150345A patent/RU2632193C2/ru active
- 2012-04-13 SI SI201231505T patent/SI3150580T1/sl unknown
- 2012-04-13 MX MX2016010614A patent/MX384521B/es unknown
- 2012-04-13 SG SG2013075478A patent/SG194447A1/en unknown
- 2012-04-13 ES ES18200713T patent/ES2886099T3/es active Active
- 2012-04-13 KR KR1020187030566A patent/KR101955871B1/ko active Active
- 2012-04-13 AR ARP120101288A patent/AR086008A1/es active IP Right Grant
- 2012-04-13 LT LTEP16172386.1T patent/LT3150580T/lt unknown
- 2012-04-13 ES ES16172386T patent/ES2706951T3/es active Active
- 2012-04-13 EP EP16172386.1A patent/EP3150580B1/en active Active
- 2012-04-13 KR KR1020257026777A patent/KR20250126865A/ko active Pending
- 2012-04-13 LT LTEP18200713.8T patent/LT3486234T/lt unknown
- 2012-04-13 KR KR1020197029487A patent/KR102154946B1/ko active Active
- 2012-04-13 HU HUE16172386A patent/HUE042788T2/hu unknown
- 2012-04-13 HU HUE18200713A patent/HUE056552T2/hu unknown
- 2012-04-13 CA CA3086473A patent/CA3086473A1/en active Pending
- 2012-04-13 MX MX2013011921A patent/MX343685B/es active IP Right Grant
- 2012-04-13 LT LTEP21175920.4T patent/LT3943485T/lt unknown
- 2012-04-13 KR KR1020217030083A patent/KR102566864B1/ko active Active
- 2012-04-13 JP JP2014505372A patent/JP5933686B2/ja active Active
- 2012-04-13 HU HUE21175920A patent/HUE066461T2/hu unknown
- 2012-04-13 PL PL21175920.4T patent/PL3943485T3/pl unknown
- 2012-04-13 BR BR122020006541-9A patent/BR122020006541B1/pt active IP Right Grant
- 2012-04-13 PH PH1/2013/502118A patent/PH12013502118A1/en unknown
- 2012-04-13 ME MEP-2016-175A patent/ME02500B/me unknown
- 2012-04-13 SI SI201232058T patent/SI3943485T1/sl unknown
- 2012-04-13 DK DK18200713.8T patent/DK3486234T3/da active
- 2012-04-13 CA CA2832843A patent/CA2832843C/en active Active
- 2012-04-13 RS RS20190065A patent/RS58226B1/sr unknown
- 2012-04-13 KR KR1020137029930A patent/KR101914321B1/ko active Active
- 2012-12-20 US US13/722,807 patent/US8765732B2/en active Active
2013
- 2013-10-06 IL IL228745A patent/IL228745A/en active IP Right Grant
- 2013-10-09 ZA ZA2013/07539A patent/ZA201307539B/en unknown
- 2013-10-10 CL CL2013002898A patent/CL2013002898A1/es unknown
- 2013-10-11 MX MX2020012695A patent/MX2020012695A/es unknown
2014
- 2014-05-12 US US14/275,667 patent/US9090562B2/en active Active
2015
- 2015-06-17 US US14/742,481 patent/US9549931B2/en active Active
- 2015-10-06 US US14/876,658 patent/US9522152B2/en active Active
2016
- 2016-03-14 JP JP2016050059A patent/JP2016147886A/ja not_active Withdrawn
- 2016-09-07 CY CY20161100879T patent/CY1117986T1/el unknown
- 2016-09-08 SM SM201600308T patent/SMT201600308B/it unknown
- 2016-11-08 US US15/346,677 patent/US10155002B2/en active Active
- 2016-11-29 IL IL249273A patent/IL249273B/en active IP Right Grant
2017
- 2017-05-17 US US15/598,078 patent/US9855275B2/en active Active
- 2017-11-17 US US15/816,907 patent/US10420775B2/en active Active
2018
- 2018-02-14 JP JP2018024505A patent/JP6778226B2/ja active Active
- 2018-09-27 JP JP2018181993A patent/JP2019014732A/ja active Pending
2019
- 2019-01-11 HR HRP20190074TT patent/HRP20190074T1/hr unknown
- 2019-01-14 CY CY191100038T patent/CY1121120T1/el unknown
- 2019-03-04 US US16/291,800 patent/US20190192526A1/en not_active Abandoned
- 2019-05-02 IL IL266418A patent/IL266418A/en active IP Right Grant
- 2019-10-22 US US16/660,339 patent/US11052093B2/en active Active
2020
- 2020-10-29 IL IL278373A patent/IL278373B1/en unknown
- 2020-11-27 JP JP2020197115A patent/JP2021042243A/ja not_active Withdrawn
2021
- 2021-05-05 US US17/308,610 patent/US20210379076A1/en not_active Abandoned
- 2021-08-31 CY CY20211100771T patent/CY1124617T1/el unknown
2022
- 2022-11-11 JP JP2022181039A patent/JP2023011933A/ja active Pending
2024
- 2024-03-15 US US18/606,903 patent/US12161645B2/en active Active
- 2024-03-15 US US18/606,925 patent/US12168015B2/en active Active
- 2024-03-15 US US18/606,946 patent/US12168016B2/en active Active
- 2024-09-27 US US18/900,199 patent/US20250170138A1/en active Pending
2025
- 2025-10-28 IL IL324294A patent/IL324294A/en unknown

Also Published As

Publication number	Publication date
TW201302704A (zh)	2013-01-16
EP3150580A1 (en)	2017-04-05
SI3943485T1 (sl)	2024-04-30
CA2832843C (en)	2020-09-29
US8410088B2 (en)	2013-04-02
CL2013002898A1 (es)	2014-08-22
RS55113B1 (sr)	2016-12-30
US20150353494A1 (en)	2015-12-10
NZ616298A (en)	2016-03-31
IL228745A0 (en)	2013-12-31
CA2832843A1 (en)	2012-10-18
RU2013150345A (ru)	2015-05-20
US20140288041A1 (en)	2014-09-25
DK3943485T3 (da)	2024-01-22
BR112013026324B1 (pt)	2020-12-08
DK3150580T3 (en)	2019-02-04
US10155002B2 (en)	2018-12-18
HK1193804A1 (zh)	2014-10-03
US12168016B2 (en)	2024-12-17
KR20140029442A (ko)	2014-03-10
SG194447A1 (en)	2013-12-30
PL3486234T3 (pl)	2021-11-29
EP2697199A1 (en)	2014-02-19
JP2019014732A (ja)	2019-01-31
KR20250126865A (ko)	2025-08-25
DK2697199T3 (en)	2016-09-12
HUE066461T2 (hu)	2024-08-28
IL278373A (lt)	2020-12-31
US20240245697A1 (en)	2024-07-25
FI3943485T3 (fi)	2024-01-29
US20130123234A1 (en)	2013-05-16
SMT201600308B (it)	2016-11-10
HRP20211297T1 (hr)	2021-12-10
LT3943485T (lt)	2024-02-12
PT3486234T (pt)	2021-09-07
KR20180120275A (ko)	2018-11-05
US10420775B2 (en)	2019-09-24
US20250170138A1 (en)	2025-05-29
JO3363B1 (ar)	2019-03-13
PL2697199T3 (pl)	2016-12-30
LT3486234T (lt)	2021-09-10
IL249273A0 (en)	2017-01-31
US9522152B2 (en)	2016-12-20
US20190192526A1 (en)	2019-06-27
KR20210118968A (ko)	2021-10-01
JOP20180104A1 (ar)	2019-01-30
US11052093B2 (en)	2021-07-06
CN104080769B (zh)	2017-06-20
IL249273B (en)	2019-05-30
KR101914321B1 (ko)	2018-11-02
PT3150580T (pt)	2019-01-28
HRP20161115T1 (hr)	2016-11-18
US20120264734A1 (en)	2012-10-18
JP2021042243A (ja)	2021-03-18
NZ717119A (en)	2017-10-27
KR102032303B1 (ko)	2019-10-15
RS62279B1 (sr)	2021-09-30
US20210379076A1 (en)	2021-12-09
CY1117986T1 (el)	2017-05-17
TWI529162B (zh)	2016-04-11
CY1121120T1 (el)	2019-12-11
ES2973868T3 (es)	2024-06-24
KR102308488B1 (ko)	2021-10-06
IL278373B1 (en)	2025-12-01
US20240245698A1 (en)	2024-07-25
ME02500B (me)	2017-02-20
RU2017132054A (ru)	2019-02-06
US8765732B2 (en)	2014-07-01
RU2017132054A3 (lt)	2021-05-14
EP3943485A1 (en)	2022-01-26
US20240277723A1 (en)	2024-08-22
SI3150580T1 (sl)	2019-03-29
KR20190121386A (ko)	2019-10-25
JP2016147886A (ja)	2016-08-18
JP2014516931A (ja)	2014-07-17
KR20190025055A (ko)	2019-03-08
US20160022693A1 (en)	2016-01-28
PT3943485T (pt)	2024-03-06
ES2886099T3 (es)	2021-12-16
IL324294A (en)	2025-12-01
AU2012242595B2 (en)	2014-05-15
NZ804540A (en)	2025-05-02
BR112013026324A8 (pt)	2018-01-30
SMT201900050T1 (it)	2019-02-28
KR101955871B1 (ko)	2019-03-08
JP6778226B2 (ja)	2020-10-28
NZ734744A (en)	2019-03-29
US12161645B2 (en)	2024-12-10
LT2697199T (lt)	2016-09-26
US9090562B2 (en)	2015-07-28
PL3150580T3 (pl)	2019-04-30
SMT202100503T1 (it)	2021-11-12
HRP20211297T8 (hr)	2022-02-18
ES2589555T3 (es)	2016-11-15
BR112013026324A2 (pt)	2016-10-11
EP3486234B1 (en)	2021-06-02
CN104080769A (zh)	2014-10-01
EP4360712A3 (en)	2024-07-31
AU2012242595A1 (en)	2013-05-02
MX2020012695A (es)	2021-04-12
US9549931B2 (en)	2017-01-24
US20180318309A1 (en)	2018-11-08
WO2012142504A1 (en)	2012-10-18
HRP20190074T1 (hr)	2019-03-08
MY166171A (en)	2018-06-07
SI2697199T1 (sl)	2016-10-28
EP4360712A2 (en)	2024-05-01
CA3086473A1 (en)	2012-10-18
DK3486234T3 (da)	2021-08-16
US20200155562A1 (en)	2020-05-21
PE20140863A1 (es)	2014-07-19
IL228745A (en)	2016-12-29
HUE028837T2 (en)	2017-01-30
IL266418A (en)	2019-06-30
EP3486234A1 (en)	2019-05-22
PH12016502132A1 (en)	2017-05-22
EP3150580B1 (en)	2018-10-17
CN107311921A (zh)	2017-11-03
MX343685B (es)	2016-11-17
HUE056552T2 (hu)	2022-02-28
PH12016502132B1 (en)	2024-01-05
PH12013502118A1 (en)	2014-01-13
RU2632193C2 (ru)	2017-10-03
SI3486234T1 (sl)	2021-12-31
EP3943485B1 (en)	2023-12-27
KR20200105543A (ko)	2020-09-07
JP5933686B2 (ja)	2016-06-15
MX384521B (es)	2025-03-14
ES2706951T3 (es)	2019-04-01
ZA201307539B (en)	2014-06-25
KR102566864B1 (ko)	2023-08-11
MX2013011921A (es)	2014-03-27
HUE042788T2 (hu)	2019-07-29
US9855275B2 (en)	2018-01-02
EP2697199B1 (en)	2016-06-08
JP2018104450A (ja)	2018-07-05
CN107311921B (zh)	2021-02-12
PT2697199T (pt)	2016-09-05
KR102154946B1 (ko)	2020-09-10
RS58226B1 (sr)	2019-03-29
AR086008A1 (es)	2013-11-13
US12168015B2 (en)	2024-12-17
JO3438B1 (ar)	2019-10-20
US20170119780A1 (en)	2017-05-04
BR122020006541B1 (pt)	2022-05-10
PL3943485T3 (pl)	2024-05-20
KR20230134128A (ko)	2023-09-20
JP2023011933A (ja)	2023-01-24
CY1124617T1 (el)	2022-07-22
US20170252349A1 (en)	2017-09-07

Publication	Publication Date	Title
IL266418A (en)	2019-06-30	Aryl or heteroaryl substituted benzene compounds
IL286152A (en)	2021-10-31	Modified imidazopyridinyl-aminopyridine compounds
IL265437A (en)	2019-05-30	Converted gasoline compounds
IL228746A0 (en)	2013-12-31	Converted gasoline compounds
GB201118652D0 (en)	2011-12-07	New compounds
GB201118654D0 (en)	2011-12-07	New compounds
HUE044576T2 (hu)	2019-11-28	Újfajta vegyületek
GB201106814D0 (en)	2011-06-01	New compounds
EP2771012A4 (en)	2015-06-24	NEW CONNECTIONS
GB201113971D0 (en)	2011-09-28	New compounds ii
GB201119591D0 (en)	2011-12-28	New compounds II
GB201119590D0 (en)	2011-12-28	New compounds I